An observational study in Cystic Fibrosis (CF), Chronic Suppurative Lung Disease and Primary Ciliary Dyskinesia (PCD), sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Imperial College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cystic Fibrosis by Imperial College London — 1 open to participants now, 1 under way, none of them phase 3. Cystic Fibrosis · Imperial College London.
Among the 10 studies in Cystic Fibrosis by Imperial College London, this one is the only one that started in 2026, is one of 5 observational ones, and was the 10th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.
Browse Cystic Fibrosis studies →1 of the 10 studies in Cystic Fibrosis by Imperial College London is open now, in 1 country.
By country, each count listing its studies:
Of the 155 Cystic Fibrosis studies recruiting now, 94 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 850 is above the median of 85 across 503 observational studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 5 interventional studies, 126 across the 5 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Cystic Fibrosis by Imperial College London, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Infections of the lungs are the most common problem for people with Cystic Fibrosis (CF), but also are significant in people with other lung conditions known generally as chronic suppurative lung diseases (CSLD), which can also cause recurrent chest infections. Some of the most common and severe infections are caused by Pseudomonas aeruginosa (Pa), Staphylococcus aureus (Sa), and Aspergillus fumigatus (Af). It is important to detect these early, in order to treat them and prevent damage to the lungs.
At the moment we rely on sputum culture or cough swabs, however, some people (for example small children or those with less severe disease) are not able to provide sputum, and cough swabs are less accurate. Additionally, although modulators such as Kaftrio and Ivacaftor have had significant positive effects on most people with CF taking them, these people often find they no longer produce sputum, and therefore we are not able to test for infections in the same way we did before. Studies have shown that although some people have fewer infections after starting modulators, they generally don't disappear altogether, and therefore we still need a reliable way to test for them.
Furthermore, we have seen that some people react differently to certain infections, and people with more than one infection simultaneously, also respond differently to these infections.
We would like to find new, reliable, easy and acceptable ways of testing for infections that does not require sputum and are acceptable for patients in order to detect, monitor and treat lung infections early. Additionally, we would like to better understand what causes the differing responses patients have to infections, in order to see if there are new ways we can target treatments.
The study is being undertaken in multiple centres across the UK in order to recruit a larger, more diverse and representative group of participants, than we would be able to achieve from one centre alone.
This study contributes towards the Cystic Fibrosis Translational Innovation Hub Network in Lung Health and Infection study: PRECISION (PolymicRobial infECtions: bIomarkerS, dIagnOstics \& mechaNisms).
Given the difficulties obtaining sputum in the current CF climate (for example, young children, those with less-advanced lung disease, and those on highly effective CFTR modulators), there is a need for alternative means for sampling to detect infections of the lower airway. This study will aim to look at such alternatives including breath analysis (exhaled volatiles), exhaled breath condensate, skin secretions, blood, stool, and urine, but will also further investigate the utility of upper airway samples such as saliva, cough swabs, throat swabs, nasal secretions, and gargles, and compare these to the traditional methods of BAL (when clinically available), and spontaneously expectorated and induced sputum.
Furthermore, current analysis of samples depends on culture, with inherent diagnostic delays which in turn can delay or result in inappropriate treatment as well as increasing the potential for cross infection between patients. There is thus a need for other options to microbial culture, for example PCR, genomics, transcriptomics and 16s gene sequencing, identification of metabolomic and proteomic biomarkers for infection using mass spectrometry and medical detection dogs, all of which have shown promise previously.
Finding reliable alternatives to sputum may also aid in future clinical trial development; currently protocols often require sputum, and thus are limited to patients who can expectorate. Such alternatives may remove this barrier, allowing these patients to benefit from such trials, but also widening the pool of recruitment, having a more accurate representation of the CF community, and thus having more reliable results.
Finally, there is a need to understand the polymicrobial nature of the CF airway, and the impacts different pathogens have on each other or the commensals (in terms of limiting or exacerbating pathogenicity, or encouraging resistance), and on the host. Sample acquisition, and outcomes from this study, will aid the research of other workstreams within the PRECISION group in developing this understanding, which may allow the identification of biomarkers for risk stratification, or targets for future drug development.
Collaboration between multiple sites throughout the UK will result in access to a larger bank of tissue samples, and differing expertise. This will enable an extremely wide breadth of data, impossible to obtain from a single centre alone, to allow us to effectively answer these questions.
Males and females with CF, other forms of chronic suppurative lung disease (CSLD) and healthy controls (HC). Selection of patients will be based on their previous clinical microbial culture results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 people with Cystic Fibrosis (pwCF)
Up to 100 patients with Chronic suppurative lung disease (CSLD)
250 Healthy controls without CF, CSLD or other chronic respiratory disease
Exploratory outcomes
Participants will provide at least one of the following samples which will be analysed by culture to determine infection status as per the current gold standards for diagnosis: 1. Bronchoalveolar lavage (only if being performed for clinical reasons) 2. Spontaneous sputum 3. Induced sputum The following other samples will be offered to participants (who may choose to perform some, or all, depending on preference): 1. Endobronchial biopsy (only collected if being performed clinically) 2. Nasal secretions 3. Saliva 4. Throat swabs 5. Cough swabs 6. Gargles 7. Breath 8. Skin secretions 9. Urine 10. Blood (only collected if being performed clinically in children) The results of these analyses will be combined with the gold standard culture results to determine their ability to identify the infection status of that particular individual. The sensitivity and specificity of these sample types and detection techniques to identify particular infections will then be calculated and compared.
Time frame: From enrollment to year 5
Utilising the results of the analyses from the primary outcome
The results of the analyses from the primary outcome will also be used to better understand the polymicrobial interactions in the Cystic Fibrosis lung, for example, competition between microbes, the changing of one microbe's behaviour in response to another, or protection from host defences, and the impact on health.
Time frame: Enrollment to year 5
Plan to share: No — Collaboration between multiple sites throughout the UK will result in access to a larger bank of tissue samples, and differing expertise. This will enable an extremely wide breadth of data, impossible to obtain from a single centre alone, to allow us to effectively answer these questions.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2029, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.